Oncology

Olive oil-based emulsion may help boost efficacy of bladder cancer therapy.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Photodynamic therapy for skin cancer can cause immense burning pain to patients.

The protein GlyRS helps modify proteins that cause cancer growth.

Research may lead to new treatments for ovarian cancer.

Doxorubicin, all-trans retinoic acid, and entinostat significantly reduced triple-negative breast cancer tumors in mice.

Driver mutations in lung adenocarcinoma and lung squamous cell carcinoma differ from one another, contradictory to previous theories.

Findings improve the ability of providers to monitor the development of melanoma.

Anthrax toxin proteins are able to control tumor growth.

Postmenopausal patients with invasive ductal carcinomas had high levels of saturated fats.

Researchers find indicators of poor chemotherapy response.

Women older than age 65 face higher risk for several comorbidities from breast cancer treatment.

Recent advances and updates in oncology and cancer drug development.

Uncialamycin may effectively treat various cancer types, including gastric, lung, and ovarian cancers.

Blocking the chemokine CXCL1 resulted in slowed growth of obesity-related prostate cancer in mice models.

Individuals with primary immunodeficiency carry increased risk of developing a variety of cancers.

The drug eCF506 can selectively block the Src tyrosine kinase and stop the growth of breast cancer cells.

Larger waist circumference associated with an increased risk of aggressive prostate cancer.

Rapalink able to inhibit growth in drug-resistant tumors across different cancer types.

An antibody showed the ability to bind to the protein Bak and cause apoptosis.

New drug class offers hope for lymphomas and leukemia.

Blocking the ERK1/2 pathway and the compensatory ERK5 pathway stopped the growth of colorectal tumors.

A method that involves a drug and a beam of ultraviolet light can kill 95% of cancer cells.

Sandoz announced efforts to create biosimilars for oncology and immunology branded drugs.

Specific blood-born microRNAs mutate before the development of hepatocellular carcinoma.

Overall survival of lung cancer patients in trial increased by 73%.

Sandoz to create biosimilars for 5 popular branded drugs.

Researchers examine the impact of aerobic and resistance training on cancer outcomes.